CN105358535B - 恩杂鲁胺制剂 - Google Patents

恩杂鲁胺制剂 Download PDF

Info

Publication number
CN105358535B
CN105358535B CN201380055471.6A CN201380055471A CN105358535B CN 105358535 B CN105358535 B CN 105358535B CN 201380055471 A CN201380055471 A CN 201380055471A CN 105358535 B CN105358535 B CN 105358535B
Authority
CN
China
Prior art keywords
grace
miscellaneous shandong
shandong amine
polymer
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380055471.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105358535A (zh
Inventor
D.A.洛伦兹
S.科纳古图
R.J.瓦尔德
J.A.艾维雷特
S.马茨
高石勇希
坂井敏郎
入江亮介
大场慎介
豊田敬康
西村浩司
上林敦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maddie Wilson LLC
Astellas Pharma Inc
Medivation Prostate Therapeutics LLC
Original Assignee
Astellas Pharma Inc
Bend Research Inc
Medivation Prostate Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105358535(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Bend Research Inc, Medivation Prostate Therapeutics LLC filed Critical Astellas Pharma Inc
Priority to CN201811517651.2A priority Critical patent/CN109897004A/zh
Publication of CN105358535A publication Critical patent/CN105358535A/zh
Application granted granted Critical
Publication of CN105358535B publication Critical patent/CN105358535B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380055471.6A 2012-09-11 2013-09-11 恩杂鲁胺制剂 Active CN105358535B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811517651.2A CN109897004A (zh) 2012-09-11 2013-09-11 恩杂鲁胺制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11
US61/699,351 2012-09-11
PCT/US2013/059223 WO2014043208A1 (en) 2012-09-11 2013-09-11 Formulations of enzalutamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811517651.2A Division CN109897004A (zh) 2012-09-11 2013-09-11 恩杂鲁胺制剂

Publications (2)

Publication Number Publication Date
CN105358535A CN105358535A (zh) 2016-02-24
CN105358535B true CN105358535B (zh) 2019-01-04

Family

ID=49231627

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380055471.6A Active CN105358535B (zh) 2012-09-11 2013-09-11 恩杂鲁胺制剂
CN201811517651.2A Pending CN109897004A (zh) 2012-09-11 2013-09-11 恩杂鲁胺制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811517651.2A Pending CN109897004A (zh) 2012-09-11 2013-09-11 恩杂鲁胺制剂

Country Status (29)

Country Link
US (10) US20140179749A1 (enExample)
EP (6) EP4450130A3 (enExample)
JP (5) JP6404217B2 (enExample)
KR (1) KR102225416B1 (enExample)
CN (2) CN105358535B (enExample)
AU (2) AU2013315619B2 (enExample)
BR (1) BR112015005432B1 (enExample)
CA (1) CA2884795C (enExample)
CY (1) CY1124729T1 (enExample)
DK (1) DK3725778T3 (enExample)
EA (2) EA201991484A1 (enExample)
ES (1) ES2892029T3 (enExample)
HK (1) HK1212701A1 (enExample)
HR (1) HRP20211423T1 (enExample)
HU (1) HUE057701T2 (enExample)
IL (1) IL237604B (enExample)
IN (1) IN2015DN02875A (enExample)
LT (1) LT3725778T (enExample)
MX (3) MX363974B (enExample)
PH (1) PH12015500525A1 (enExample)
PL (1) PL3725778T3 (enExample)
PT (1) PT3725778T (enExample)
RS (1) RS62676B1 (enExample)
SI (1) SI3725778T1 (enExample)
SM (1) SMT202100550T1 (enExample)
TW (1) TWI673051B (enExample)
UA (1) UA117353C2 (enExample)
WO (1) WO2014043208A1 (enExample)
ZA (1) ZA201501847B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
PT3305285T (pt) 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
BR112015026257B1 (pt) * 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
MX386859B (es) * 2014-02-05 2025-03-19 Lek Pharmaceuticals Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
BR112017011788A2 (pt) 2014-12-05 2017-12-26 Aragon Pharmaceuticals Inc composições anticâncer
CA2969675C (en) 2014-12-05 2023-06-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
CR20170217A (es) * 2014-12-05 2017-08-30 Aragon Pharmaceuticals Inc Composiciones anticancerígenas
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
CA2976360A1 (en) * 2015-02-11 2016-08-18 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
US20180235935A1 (en) 2015-08-12 2018-08-23 Medivation Prostate Therapeutics Llc Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017058869A1 (en) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
ES2900149T3 (es) 2016-07-21 2022-03-16 Hadasit Med Res Service Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma
EP3500310A1 (en) 2016-08-20 2019-06-26 FTF Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
BR112019021324A2 (pt) * 2017-04-13 2020-06-16 Paul Remon Jean Composições baseadas em xanthohumol
JP7172997B2 (ja) * 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
WO2019030691A1 (en) * 2017-08-08 2019-02-14 Dr. Reddy’S Laboratories Limited EXTRUDED COMPOSITIONS OF ENZALUTAMIDE
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US20200397756A1 (en) * 2018-02-09 2020-12-24 Kashiv Biosciences, Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
JP7244536B2 (ja) * 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
US12358870B2 (en) 2018-10-30 2025-07-15 Peloton Therapeutics, Inc. Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
EA202191372A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Таблетка и способ получения таблетки
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144646A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Apalutamide dispersed in applesauce for treating prostate cancer
WO2020157699A1 (en) 2019-01-30 2020-08-06 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
BR112021014657A2 (pt) 2019-01-30 2021-09-21 Janssen Pharmaceutica N.V. Métodos para tratar câncer de próstata com base em subtipos moleculares
CA3139380A1 (en) 2019-05-16 2020-11-19 Leon-Nanodrugs Gmbh Method for producing nanoparticles
JP2022533463A (ja) 2019-05-23 2022-07-22 ヘルム・アクチエンゲゼルシャフト エンザルタミドを含むナノ粒子
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220242829A1 (en) 2019-06-27 2022-08-04 Synthon B.V. Process for preparation of enzalutamide
CN119424433A (zh) * 2019-09-18 2025-02-14 百时美施贵宝公司 Tyk2抑制剂的剂型
CN118319863A (zh) * 2019-09-23 2024-07-12 生态有限公司 治疗制剂及其用途
WO2021064123A1 (en) 2019-10-03 2021-04-08 Synthon B.V. Pharmaceutical composition comprising enzalutamide
EP4054572A1 (en) 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
JP2023524661A (ja) * 2020-05-06 2023-06-13 ディスラプティヴ ファーマ エービー 新規非晶質活性医薬成分
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN114053243B (zh) * 2020-08-05 2024-11-12 齐鲁制药有限公司 一种恩扎卢胺软胶囊及其制备方法
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
SMT202500315T1 (it) * 2020-09-09 2025-11-10 Crinetics Pharmaceuticals Inc Formulazioni di un modulatore della somatostatina
BR112023004824A2 (pt) * 2020-09-18 2023-04-18 Bristol Myers Squibb Co Formas de dosagem para inibidores tyk2 compreendendo núcleos intumescíveis
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
MX2023012597A (es) 2021-07-07 2023-12-07 Bdr Pharmaceuticals Intl Pvt Ltd Nuevas composiciones liquidas orales de enzalutamida y metodo de fabricacion de las mismas.
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
CN118251213A (zh) * 2022-01-19 2024-06-25 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide
WO2024191660A2 (en) * 2023-03-10 2024-09-19 Yale University Compositions and methods for treating steroid hormone-related diseases or disorders
WO2024189186A1 (en) 2023-03-16 2024-09-19 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer
WO2025052925A1 (ja) * 2023-09-08 2025-03-13 沢井製薬株式会社 エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
EP4520322A1 (en) * 2023-12-06 2025-03-12 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical compositions containing enzalutamide
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法
WO2025212071A1 (en) * 2024-04-05 2025-10-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A solid dispersion of enzalutamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241946A (zh) * 1996-12-25 2000-01-19 山之内制药株式会 快速崩解性医药组合物
CN1787808A (zh) * 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
US20070004753A1 (en) * 2005-05-13 2007-01-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2011106570A1 (en) * 2010-02-24 2011-09-01 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
IN191496B (enExample) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
DE60206889T2 (de) 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
AU2003229912A1 (en) 2002-04-18 2003-11-03 Avecia Limited Prepation of a conjugated molecule and materials for use therein
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
US20050020675A1 (en) * 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
WO2005095950A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
EP1885338A1 (en) * 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
CN101277682B (zh) 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
PL3412290T3 (pl) 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2134327A1 (en) 2007-03-13 2009-12-23 Sandoz AG Pharmaceutical compositions of poorly soluble drugs
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
MX2011008303A (es) 2009-04-03 2011-11-29 Plexxikon Inc Composiciones del acido propano-1-sulfonico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil}-amida y el uso de las mismas.
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
UA104517C2 (uk) * 2010-03-10 2014-02-10 Ебботт Леборетріз Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
ES2809738T3 (es) 2012-06-07 2021-03-05 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador de receptor de andrógenos
EP2883271B1 (en) * 2012-08-10 2020-07-22 Keyssa, Inc. Dielectric coupling systems for ehf communications
BR112015005404A2 (pt) 2012-09-11 2017-08-22 Dr Reddys Laboratories Ltd Formas polimórficas de enzalutamida e sua preparação
WO2014042945A1 (en) 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP7172997B2 (ja) 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
WO2021064123A1 (en) 2019-10-03 2021-04-08 Synthon B.V. Pharmaceutical composition comprising enzalutamide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241946A (zh) * 1996-12-25 2000-01-19 山之内制药株式会 快速崩解性医药组合物
CN1787808A (zh) * 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
US20070004753A1 (en) * 2005-05-13 2007-01-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2011106570A1 (en) * 2010-02-24 2011-09-01 Medivation Prostate Therapeutics, Inc. Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds

Also Published As

Publication number Publication date
JP2016204392A (ja) 2016-12-08
CA2884795A1 (en) 2014-03-20
US20140179749A1 (en) 2014-06-26
EP4450130A2 (en) 2024-10-23
US11839689B2 (en) 2023-12-12
PT3725778T (pt) 2021-09-22
US20140100256A1 (en) 2014-04-10
ZA201501847B (en) 2016-01-27
EA201500314A1 (ru) 2015-12-30
JP2021178871A (ja) 2021-11-18
US20200060976A1 (en) 2020-02-27
AU2013315619A1 (en) 2015-04-30
JP2018087206A (ja) 2018-06-07
SI3725778T1 (sl) 2022-02-28
AU2013315619B2 (en) 2018-02-08
KR102225416B1 (ko) 2021-03-09
RS62676B1 (sr) 2021-12-31
US20250049721A1 (en) 2025-02-13
DK3725778T3 (da) 2021-09-20
MX2021000007A (es) 2021-03-09
ES2892029T3 (es) 2022-02-01
AU2018200316A1 (en) 2018-02-08
US20230210778A1 (en) 2023-07-06
US20170027910A1 (en) 2017-02-02
BR112015005432A2 (enExample) 2017-09-05
TWI673051B (zh) 2019-10-01
UA117353C2 (uk) 2018-07-25
US20230122911A1 (en) 2023-04-20
EP3971167A1 (en) 2022-03-23
KR20150082203A (ko) 2015-07-15
US20190209476A1 (en) 2019-07-11
EP4324527A2 (en) 2024-02-21
JP6932746B2 (ja) 2021-09-08
EA033374B9 (ru) 2019-12-18
BR112015005432B1 (pt) 2023-04-18
IN2015DN02875A (enExample) 2015-09-11
CA2884795C (en) 2023-10-17
EP4169908A1 (en) 2023-04-26
MX2015003140A (es) 2015-12-16
MX363974B (es) 2019-04-10
JP2019194262A (ja) 2019-11-07
EP3725778B1 (en) 2021-08-18
EA033374B1 (ru) 2019-10-31
TW201427659A (zh) 2014-07-16
IL237604A0 (en) 2015-04-30
JP6404217B2 (ja) 2018-10-10
HK1212701A1 (zh) 2016-06-17
HUE057701T2 (hu) 2022-05-28
US12447128B2 (en) 2025-10-21
EA201991484A1 (ru) 2019-11-29
IL237604B (en) 2021-07-29
HRP20211423T1 (hr) 2022-01-21
US20170224624A1 (en) 2017-08-10
LT3725778T (lt) 2021-12-27
JP2015527411A (ja) 2015-09-17
CN105358535A (zh) 2016-02-24
EP3725778A1 (en) 2020-10-21
CY1124729T1 (el) 2022-07-22
PH12015500525A1 (en) 2015-05-04
SMT202100550T1 (it) 2022-01-10
EP2895463A1 (en) 2015-07-22
US20140378517A1 (en) 2014-12-25
PL3725778T3 (pl) 2021-12-20
WO2014043208A1 (en) 2014-03-20
CN109897004A (zh) 2019-06-18
MX2019003984A (es) 2019-08-12
EP4324527A3 (en) 2024-04-24
EP4450130A3 (en) 2025-01-08
US20250090465A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
CN105358535B (zh) 恩杂鲁胺制剂
CN105640890B (zh) 一种难溶性活性成分微粒、微粒制剂及其制备方法
KR20150097792A (ko) 개선된 생체이용률을 갖는 약학 조성물
US20200078463A1 (en) Composition having improved water solubility and bioavailability
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
US9775832B2 (en) Pharmaceutical composition for oral administration
US12502357B2 (en) Formulations of enzalutamide
HK40116766A (en) Formulations of enzalutamide
HK40108713A (en) Formulations of enzalutamide
Singh Formulation and evaluation of sustained release dosage form of selected drug using release eudragits

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Medical Management Co.,Ltd.

Applicant after: BEND RESEARCH

Applicant after: ASTELLAS PHARMA Inc.

Address before: California, USA

Applicant before: MEDIVATION PROSTATE THERAPEUTICS, Inc.

Applicant before: BEND RESEARCH

Applicant before: ASTELLAS PHARMA Inc.

CB02 Change of applicant information
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: MEDIVATION PROSTATE THERAPEUTICS Inc.

Applicant after: BEND RESEARCH

Applicant after: ASTELLAS PHARMA Inc.

Address before: California, USA

Applicant before: Medical Management Co.,Ltd.

Applicant before: BEND RESEARCH

Applicant before: ASTELLAS PHARMA Inc.

TA01 Transfer of patent application right

Effective date of registration: 20180503

Address after: California, USA

Applicant after: MEDIVATION PROSTATE THERAPEUTICS Inc.

Applicant after: ASTELLAS PHARMA Inc.

Address before: California, USA

Applicant before: MEDIVATION PROSTATE THERAPEUTICS Inc.

Applicant before: Maddie Wilson LLC

Applicant before: ASTELLAS PHARMA Inc.

Effective date of registration: 20180503

Address after: California, USA

Applicant after: MEDIVATION PROSTATE THERAPEUTICS Inc.

Applicant after: Maddie Wilson LLC

Applicant after: ASTELLAS PHARMA Inc.

Address before: California, USA

Applicant before: MEDIVATION PROSTATE THERAPEUTICS Inc.

Applicant before: BEND RESEARCH

Applicant before: ASTELLAS PHARMA Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: New York State, USA

Patentee after: MEDIVATION PROSTATE THERAPEUTICS Inc.

Patentee after: Astellas Pharma Inc.

Address before: California, USA

Patentee before: MEDIVATION PROSTATE THERAPEUTICS Inc.

Patentee before: Astellas Pharma Inc.

CP02 Change in the address of a patent holder